Aldeyra Therapeutics, Inc to Post Q2 2018 Earnings of ($0.39) Per Share, Seaport Global Securities F

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Stock analysts at Seaport Global Securities issued their Q2 2018 EPS estimates for Aldeyra Therapeutics in a note issued to investors on Wednesday, May 16th. Seaport Global Securities analyst C. Davis forecasts that the biotechnology company will earn ($0.39) per share for the quarter. Seaport Global Securities has a “Buy” rating on the stock.

Get Aldeyra Therapeutics alerts:

Several other brokerages also recently weighed in on ALDX. Canaccord Genuity restated a “buy” rating and issued a $27.00 target price on shares of Aldeyra Therapeutics in a research note on Tuesday, March 13th. Cantor Fitzgerald set a $23.00 target price on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Tuesday. ValuEngine upgraded shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 4th. Finally, Cowen restated a “hold” rating on shares of Aldeyra Therapeutics in a research note on Monday, April 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $16.93.

Shares of Aldeyra Therapeutics opened at $9.17 on Friday, Marketbeat Ratings reports. The firm has a market capitalization of $178.97 million, a PE ratio of -6.55 and a beta of 0.55. The company has a quick ratio of 13.12, a current ratio of 11.09 and a debt-to-equity ratio of 0.03. Aldeyra Therapeutics has a twelve month low of $8.35 and a twelve month high of $8.50.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Tuesday, May 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06).

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its holdings in Aldeyra Therapeutics by 19.8% in the first quarter. JPMorgan Chase & Co. now owns 59,502 shares of the biotechnology company’s stock valued at $446,000 after acquiring an additional 9,826 shares in the last quarter. Woodstock Corp raised its holdings in Aldeyra Therapeutics by 20.4% in the fourth quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock valued at $396,000 after acquiring an additional 9,850 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Aldeyra Therapeutics by 22.6% in the first quarter. Dimensional Fund Advisors LP now owns 62,429 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 11,506 shares in the last quarter. Northern Trust Corp raised its holdings in Aldeyra Therapeutics by 34.3% in the first quarter. Northern Trust Corp now owns 48,151 shares of the biotechnology company’s stock valued at $361,000 after acquiring an additional 12,290 shares in the last quarter. Finally, Element Capital Management LLC acquired a new stake in Aldeyra Therapeutics in the first quarter valued at $123,000. 50.13% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sj枚gren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.